Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19

Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19

WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More

Thursday April 29, 2021 0 comments Tags: Westminster, Reven Holdings, COVID-19, Fatih Uckun, Peter Lange, Michael Volk, Brian Denomme

Reven Pharmaceuticals wins FDA nod of IND application for COVID treatment with Rejuveinix

Reven Pharmaceuticals wins FDA nod of IND application for COVID treatment with Rejuveinix

GOLDEN -- Reven today announced the U.S. Food and Drug Administration has approved its Investigational New Drug application in connection with its lead anti-inflammatory/anti-oxidant... Read More

Thursday October 22, 2020 0 comments Tags: Golden, Reven Pharmaceuticals, Reven Holdings, Rejuveinix, COVID-19, Fatih Uckun, Michael Volk, Peter Lange

Reven selects eClinical services provider DSG to accelerate Reven’s RJX as treatment for COVID-19

Reven selects eClinical services provider DSG to accelerate Reven’s RJX as treatment for COVID-19

GOLDEN -- Reven Holdings, Inc. today announced it selected DSG, Inc., a leading global eClinical services provider, for all aspects of clinical trial data management during its upcoming COVID-19... Read More

Wednesday September 30, 2020 0 comments Tags: Golden, Reven Holdings, Reven Pharmaceuticals, DSG, Fatih Uckun, Michael Volk, Tony Varano, COVID-19

Reven’s patented treatment platform for sepsis on track for testing COVID-19 patients

Reven’s patented treatment platform for sepsis on track for testing COVID-19 patients

GOLDEN -- Reven Holdings, a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral... Read More

Tuesday September 15, 2020 0 comments Tags: Golden, Reven Holdings, Reven Pharmaceuticals, COVID-19, Michael Volk, Fatih Uckun, Rejuveinix